References
- James VHT, Reed MJ. Steroid hormones and human cancer. Prog Cancer Res Ther 1980;14:471–87
- Bernstein L, Ross RK. Endogenous hormones and breast cancer risk. Epidemiol Rev 1993;15:48–65
- Siiteri PK, MacDonald PC. Role of extraglandular estrogen in human endocrinology. In Greep RO, Astwood EB (Eds), Handbook of Physiology. Washington DC: American Physiological Society, 1973;2:615–29
- Reed MJ, Hutton JD, Baxendale PM et al. The conversion of androstenedione to oestrone and production of oestrone in women with endometrial cancer. J Steroid Biochem 1979;11:905–11
- Grodin JM, Siiteri PK, MacDonald PC. Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 1973;36:207–14
- Dunn LJ, Bradbury JT. Endocrine factors in endometrial carcinoma: a preliminary report. Am J Obstet Gynecol 1967;97:465–71
- Hemsell DL, Grodin JM, Brenner PF et al. Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. J Clin Endocrin Metab 1974;38:476–9
- Buzdar AU, Jonat W, Howell A et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 1998;83:1142–52
- Dombernowsky P, Smith I, Falkson G et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomised trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998;16:453–61
- Gershanovich M, Chaudhuri HA, Campos D et al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann Oncol 1998;9: 639–45
- Dowsett M, Geisler J, Haynes BP et al. Letrozole achieves more complete inhibition of whole body aromatisation than anastrozole. Eur J Cancer 2000;36:S88–S89
- Kaufmann M, Bajeta E, Dirix LY et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomised double blind trials. J Clin Oncol 2000;18:1399–1411
- Buzdar A, Nabholtz JM, Robertson JF et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Combined analysis from two identically designed multicentre trials. Proc Am Soc Clin Oncol 2000;154a:Abstr 609D
- Nabholtz JM, Budzar A, Pollak M et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 2000;18:3758–67
- Bonneterre J, Thurlimann B, Robertson JFR et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol 2000;18:3748–57
- Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596–606
- Parideans R, Dirix LY, Beex L et al. Exemestane (Aromasin) is active and well tolerated as first line hormonal therapy of metastatic breast cancer patients: results of a randomized phase II trial. Proc Am Soc Clin Oncol 2000;83a:Abstr 316
- Boccardo F, Rubagotti A, Amoroso D et al. Tamoxifen vs aminoglutethimide in breast cancer patients previously treated with adjuvant tamoxifen. Preliminary results of a multicentric comparative study. Proc Am Soc Clin Oncol 2000;71a:Abstr 273
- Ellis MJ, Jaenicke F, Llombart-Cussac A et al. A randomized double-blind multicentre study of preoperative tamoxifen versus Femara (letrozole) for postmenopausal women with ER and/or PgR positive breast cancer ineligible for breast conserving surgery – correlation of clinical response with tumour gene expression and proliferation. Breast Cancer Res Treat 2000;64:29